A new trading day began on Tuesday, with Celldex Therapeutics Inc (NASDAQ: CLDX) stock price up 3.05% from the previous day of trading, before settling in for the closing price of $26.21. CLDX’s price has ranged from $24.43 to $53.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 30.09% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 15.95%. With a float of $64.15 million, this company’s outstanding shares have now reached $66.34 million.
In an organization with 160 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 76.63%, operating margin of -1645.68%, and the pretax margin is -1544.48%.
Celldex Therapeutics Inc (CLDX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 3.31%, while institutional ownership is 106.38%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares. Before that another transaction happened on Jun 14 ’24, when Company’s SVP AND CFO sold 17,172 for $35.42, making the entire transaction worth $608,315. This insider now owns 28,125 shares in total.
Celldex Therapeutics Inc (CLDX) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.83 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.95% per share during the next fiscal year.
Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators
Here are Celldex Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 24.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 179.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.57, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.23 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc (CLDX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.2 million. That was better than the volume of 0.87 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 55.10%. Additionally, its Average True Range was 1.67.
During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 11.43%, which indicates a significant decrease from 52.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.81% in the past 14 days, which was lower than the 58.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.00, while its 200-day Moving Average is $37.26. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $27.83. Second resistance stands at $28.66. The third major resistance level sits at $29.42. If the price goes on to break the first support level at $26.25, it is likely to go to the next support level at $25.49. The third support level lies at $24.66 if the price breaches the second support level.
Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats
With a market capitalization of 1.79 billion, the company has a total of 66,344K Shares Outstanding. Currently, annual sales are 6,880 K while annual income is -141,430 K. The company’s previous quarter sales were 3,190 K while its latest quarter income was -42,120 K.
